S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid

[1]  T. Ruzicka,et al.  Bullous pemphigoid. , 2017, Autoimmunity reviews.

[2]  L. Marshall,et al.  Pemphigus , 2017, Nature Reviews Disease Primers.

[3]  D. Zillikens,et al.  Malignancies in pemphigus and pemphigoid diseases. , 2015, The Journal of investigative dermatology.

[4]  D. Zillikens,et al.  Serum autoantibodies against the dermal–epidermal junction in patients with chronic pruritic disorders, elderly individuals and blood donors prospectively recruited , 2014, The British journal of dermatology.

[5]  K. Peris,et al.  Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. , 2013, Journal of the American Academy of Dermatology.

[6]  D. Zillikens,et al.  Pemphigoid diseases , 2013, The Lancet.

[7]  D. Zillikens,et al.  Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. , 2012, Journal of the American Academy of Dermatology.

[8]  F. Wojnarowska,et al.  The associations between bullous pemphigoid and drug use: a UK case-control study. , 2013, JAMA dermatology.

[9]  M. Goldacre,et al.  Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011 , 2013, Archives of Dermatological Research.

[10]  M. Alaibac,et al.  Biochip Technology for the Serological Diagnosis of Bullous Pemphigoid , 2012, ISRN dermatology.

[11]  D. Giavarina,et al.  Diagnostic accuracy of enzyme-linked immunosorbent assays (ELISA) to detect anti-skin autoantibodies in autoimmune blistering skin diseases: a systematic review and meta-analysis. , 2012, Autoimmunity reviews.

[12]  L. Naldi,et al.  Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort , 2012, The British journal of dermatology.

[13]  N. Bizzaro,et al.  Anti-Skin Specific Autoantibodies Detected by a New Immunofluorescence Multiplex Biochip Method in Patients with Autoimmune Bullous Diseases , 2012, Dermatology.

[14]  D. Zillikens,et al.  Serological diagnosis of autoimmune bullous skin diseases: Prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy , 2012, Orphanet Journal of Rare Diseases.

[15]  H. Gollnick,et al.  Diagnostics of autoimmune bullous diseases in German dermatology departments , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[16]  D. Zillikens,et al.  Epitope mapping of BP230 leading to a novel enzyme‐linked immunosorbent assay for autoantibodies in bullous pemphigoid , 2012, The British journal of dermatology.

[17]  H. Shimizu,et al.  Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. , 2012, Journal of the American Academy of Dermatology.

[18]  S. Grando.  Pemphigus autoimmunity: Hypotheses and realities , 2011, Autoimmunity.

[19]  M. Hertl,et al.  Autoimmune bullous skin diseases. Part 2: diagnosis and therapy , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[20]  F. Sera,et al.  Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. , 2011, The Journal of investigative dermatology.

[21]  M. Hertl,et al.  Autoimmune bullous skin diseases. Part 1: Clinical manifestations , 2011, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[22]  M. Hertl,et al.  Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin‐332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients , 2011, The British journal of dermatology.

[23]  Tzeng-Ji Chen,et al.  Comorbidity profiles among patients with bullous pemphigoid: a nationwide population‐based study , 2011, The British journal of dermatology.

[24]  L. Naldi,et al.  Mortality of bullous pemphigoid in Switzerland: a prospective study , 2011, The British journal of dermatology.

[25]  L. Borradori,et al.  Clinical features and practical diagnosis of bullous pemphigoid. , 2011, Dermatologic clinics.

[26]  Y. Shirakata,et al.  Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. , 2011, Journal of dermatological science.

[27]  J. Roujeau,et al.  Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. , 2011, The Journal of investigative dermatology.

[28]  S. Langan,et al.  The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. , 2011, The Journal of investigative dermatology.

[29]  P. Tuchinda,et al.  Prevalence and clinical features of Thai patients with bullous pemphigoid. , 2011, Asian Pacific journal of allergy and immunology.

[30]  F. Antonicelli,et al.  Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. , 2011, Archives of dermatology.

[31]  Z. Randriamanantany,et al.  Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. , 2011, Archives of dermatology.

[32]  D. Zillikens,et al.  The diagnosis and treatment of autoimmune blistering skin diseases. , 2011, Deutsches Arzteblatt international.

[33]  Enno Schmidt,et al.  Modern diagnosis of autoimmune blistering skin diseases. , 2010, Autoimmunity reviews.

[34]  A. Vincent,et al.  The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. , 2010, Archives of dermatology.

[35]  R. Silvestrini,et al.  False‐positive intercellular cement substance antibodies due to group A/B red cell antibodies: frequency and approach , 2010, Pathology.

[36]  T. Hashimoto,et al.  The Protease Inhibitor Alpha-2-Macroglobuline-Like-1 Is the p170 Antigen Recognized by Paraneoplastic Pemphigus Autoantibodies in Human , 2010, PloS one.

[37]  D. Zillikens,et al.  Clinical and immunopathological spectrum of paraneoplastic pemphigus , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[38]  D. Zillikens,et al.  Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania , 2010, International journal of dermatology.

[39]  E. Bröcker,et al.  Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients , 2010, Experimental dermatology.

[40]  T. Pavlík,et al.  Bullous pemphigoid and internal diseases - A case-control study. , 2010, European journal of dermatology : EJD.

[41]  A. Weaver,et al.  Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. , 2010, Archives of dermatology.

[42]  D. Zillikens,et al.  Development of ELISA for the specific determination of autoantibodies against envoplakin and periplakin in paraneoplastic pemphigus. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[43]  R. Müllegger,et al.  Autoantibodies against desmocollins in European patients with pemphigus , 2009, Clinical and experimental dermatology.

[44]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[45]  L. Naldi,et al.  Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2‐year prospective study , 2009, The British journal of dermatology.

[46]  G. Vena,et al.  Evaluation of a New ELISA Assay for Detection of BP230 Autoantibodies in Bullous Pemphigoid , 2009, Annals of the New York Academy of Sciences.

[47]  A. Kerstan,et al.  Histopathology of anti-laminin 5 mucous membrane pemphigoid. , 2009, Journal of the American Academy of Dermatology.

[48]  H. Mouquet,et al.  ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. , 2009, Archives of dermatology.

[49]  R. Eming,et al.  Clinical and Immunological Follow-Up of Pemphigus Patients on Adjuvant Treatment with Immunoadsorption or Rituximab , 2008, Dermatology.

[50]  F. Sera,et al.  Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. , 2008, Clinical immunology.

[51]  L. Diaz,et al.  E-cadherin is an additional immunological target for pemphigus autoantibodies. , 2008, The Journal of investigative dermatology.

[52]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[53]  M. Hertl,et al.  IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris , 2007, Experimental dermatology.

[54]  L. Vaillant,et al.  Neurological Disorders in Patients with Bullous Pemphigoid , 2007, Dermatology.

[55]  D. Zillikens,et al.  Enzyme‐linked immunosorbent assay using multimers of the 16th non‐collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies , 2007, Experimental dermatology.

[56]  D. Zillikens,et al.  Histopathology of Anti-p200 Pemphigoid , 2007, The American Journal of dermatopathology.

[57]  G. Zambruno,et al.  The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. , 2007, The Journal of investigative dermatology.

[58]  A. Markopoulos,et al.  Epidemiologic survey of pemphigus vulgaris with oral manifestations in northern Greece: Retrospective study of 129 patients , 2007, International journal of dermatology.

[59]  L. Borradori,et al.  Bullous pemphigoid: physiopathology, clinical features and management. , 2007, Advances in dermatology.

[60]  A. Parodi,et al.  Antidesmoplakin antibodies in pemphigus vulgaris , 2006, The British journal of dermatology.

[61]  K. Hashimoto,et al.  Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. , 2006, Journal of dermatological science.

[62]  S. Tan,et al.  Comparison of desmoglein ELISA and indirect immunofluorescence using two substrates (monkey oesophagus and normal human skin) in the diagnosis of pemphigus , 2005, The Australasian journal of dermatology.

[63]  R. Bergman,et al.  A comparison of anti‐desmoglein antibodies and indirect immunofluorescence in the serodiagnosis of pemphigus vulgaris , 2005, International journal of dermatology.

[64]  Z. Naraghi,et al.  Pemphigus: Analysis of 1209 cases , 2005, International journal of dermatology.

[65]  R. Vodegel,et al.  Clinical and Laboratory Investigations U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases , 2004 .

[66]  Y. Chan,et al.  Comparison of immunofluorescence microscopy, immunoblotting and enzyme‐linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid , 2003, Clinical and experimental dermatology.

[67]  T. Nishikawa,et al.  BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. , 2002, Journal of dermatological science.

[68]  J. Bystryn,et al.  Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus. , 2002, Archives of dermatology.

[69]  T. Nishikawa,et al.  Monitoring disease activity in pemphigus with enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 , 2002, The British journal of dermatology.

[70]  D. West,et al.  The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. , 2002, Archives of dermatology.

[71]  T. Gordon,et al.  Antibodies to Blood Group Antigens Mimic Pemphigus Staining Patterns: A Useful Reminder , 2002, Autoimmunity.

[72]  D. Zillikens,et al.  Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.

[73]  S. Jabłońska,et al.  The use of two substrates for indirect immunofluorescence in the diagnosis of pemphigus , 2001, The British journal of dermatology.

[74]  Y. Amo,et al.  Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. , 2001, Journal of dermatological science.

[75]  P. Seed,et al.  The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels , 2001, The British journal of dermatology.

[76]  B. Rzany,et al.  Klinik und Immunpathologie bei 48 Patienten mit Pemphigus , 2000, Der Hautarzt.

[77]  S. Grando,et al.  Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. , 2000, The American journal of pathology.

[78]  P. Courville,et al.  Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. , 2000, Journal of the American Academy of Dermatology.

[79]  S. Grando,et al.  Pemphigus Vulgaris Antibody Identifies Pemphaxin , 2000, The Journal of Biological Chemistry.

[80]  S. Challacombe,et al.  The use of two substrates to improve the sensitivity of indirect immunofluorescence in the diagnosis of pemphigus , 2000, The British journal of dermatology.

[81]  S. Challacombe,et al.  Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3 , 2000, Clinical and experimental dermatology.

[82]  E. Bröcker,et al.  Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. , 2000, Archives of dermatology.

[83]  A. Roth,et al.  Immunpathologische Veränderungen bei 115 Patienten mit bullösem Pemphigoid , 1999, Der Hautarzt.

[84]  Zhi Hong Wang,et al.  Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. , 1999, The Journal of clinical investigation.

[85]  T. Nishikawa,et al.  The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. , 1999, Journal of the American Academy of Dermatology.

[86]  P. Lenz,et al.  Desmoglein 3-ELISA: a pemphigus vulgaris-specific diagnostic tool. , 1999, Archives of dermatology.

[87]  E. Bröcker,et al.  [Immunopathologic changes in 115 patients with bullous pemphigoid]. , 1999, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[88]  T. Nishikawa,et al.  Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice. , 1998, The Journal of clinical investigation.

[89]  J. Uitto,et al.  The members of the plakin family of proteins recognized by paraneoplastic pemphigus antibodies include periplakin. , 1998, The Journal of investigative dermatology.

[90]  D. Zillikens,et al.  Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. , 1997, The Journal of investigative dermatology.

[91]  X Ding,et al.  Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. , 1997, The Journal of investigative dermatology.

[92]  Y. Kwon,et al.  cDNA cloning of the 210-kDa paraneoplastic pemphigus antigen reveals that envoplakin is a component of the antigen complex. , 1997, The Journal of investigative dermatology.

[93]  J. Nicolas,et al.  Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. , 1997, Archives of dermatology.

[94]  T. Nishikawa,et al.  Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. , 1997, Journal of immunology.

[95]  J. Bystryn,et al.  Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus. , 1997, Journal of the American Academy of Dermatology.

[96]  Jean Kanitakis,et al.  Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2 , 1996, The British journal of dermatology.

[97]  L. Vaillant,et al.  Drugs Associated With Bullous Pemphigoid: A Case-Control Study , 1996 .

[98]  H. Pas,et al.  Bullous pemphigoid: serum antibody titre and antigen specificity , 1995, Experimental dermatology.

[99]  S. Imamura,et al.  The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. , 1995, Journal of dermatological science.

[100]  B. Zelickson,et al.  Bullous pemphigoid and herpes gestationis autoantibodies recognize a common non-collagenous site on the BP180 ectodomain. , 1993, Journal of immunology.

[101]  P. Joly,et al.  [Paraneoplastic pemphigus]. , 1993, Presse medicale.

[102]  R. Wolf,et al.  Drug-induced versus drug-triggered pemphigus. , 1991, Dermatologica.

[103]  S. Kim,et al.  Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia , 1991, The New England journal of medicine.

[104]  E. Beutner,et al.  Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. , 1990, Journal of the American Academy of Dermatology.

[105]  G. Eklund,et al.  Pemphigoid and cancer. , 1990, Archives of dermatology.

[106]  D. Mutasim,et al.  Drug-induced pemphigus. , 1993, Dermatologic clinics.

[107]  F. Wojnarowska,et al.  The use of chemically split tissue in the detection of circulating anti‐basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid , 1988, The British journal of dermatology.

[108]  M. Sabolinski,et al.  Substrate specificity of anti-epithelial antibodies of pemphigus vulgaris and pemphigus foliaceus sera in immunofluorescence tests on monkey and guinea pig esophagus sections. , 1987, The Journal of investigative dermatology.

[109]  M. Leibowitch,et al.  [Induced pemphigus]. , 1987, Annales de dermatologie et de venereologie.

[110]  V. Ruocco,et al.  Drug-induced pemphigus. , 1998, Clinics in dermatology.

[111]  A. Inman,et al.  Differentiating anti-lamina lucida and anti-sublamina densa anti-BMZ antibodies by indirect immunofluorescence on 1.0 M sodium chloride-separated skin. , 1984, The Journal of investigative dermatology.

[112]  Ahmed Ar,et al.  Anti-Intercellular Substance Antibodies: Presence in Serum Samples of 14 Patients Without Pemphigus , 1983 .

[113]  A. Ahmed,et al.  Anti-intercellular substance antibodies. Presence in serum samples of 14 patients without pemphigus. , 1983, Archives of dermatology.

[114]  J. Hietanen,et al.  Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. , 1982, Acta dermato-venereologica.

[115]  R. Kaslow,et al.  Pemphigus in Hartford County, Connecticut, from 1972 to 1977. , 1980, Archives of dermatology.

[116]  R. Fitzpatrick,et al.  The correlation of disease activity and antibody titers in pemphigus. , 1980, Archives of dermatology.

[117]  Y. Sharav,et al.  Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. , 1974, Oral surgery, oral medicine, and oral pathology.

[118]  E. Beutner,et al.  The immunopathology of pemphigus and bullous pemphigoid. , 1989, The Journal of investigative dermatology.

[119]  E. Beutner,et al.  The Immunopathology of Pemphigus and Bullous Pemphigoid**From the Department of Microbiology, SUNY at Buffalo School of Medicine, Buffalo, New York, Mayo Graduate School of Medicine, Rochester, Minn., and the Department of Dermatology, Warsaw Medical School, Warsaw, Poland. , 1968 .

[120]  E. Beutner,et al.  Basement zone antibodies in bullous pemphigoid. , 1967, JAMA.